Pemrydi RTU access guide: country options for cross-border named-patient access
Editorial and clinical review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.
About Pemrydi RTU
Pemrydi RTU (pemetrexed (ready-to-use)) is a folate antimetabolite chemotherapy (ready-to-use formulation) approved by the US Food and Drug Administration for non-squamous non-small cell lung cancer and malignant pleural mesothelioma, in combinations or monotherapy per the labeled regimens. The current FDA label is available at accessdata.fda.gov. Pemrydi RTU is marketed by Avenacy [fact -- to confirm]. Reserve Meds coordinates US-sourced cross-border access to Pemrydi RTU under the named-patient and personal-import framework that governs reference-authority-approved medicines in the patient jurisdiction, with chain-of-custody documentation under the US Drug Supply Chain Security Act (DSCSA). The country-specific access guides listed below set out the regulatory pathway, the tertiary referral context, the documentation bundle the treating physician of record submits to the regulator, and the indicative drug-only cash-pay band for Pemrydi RTU in each jurisdiction Reserve Meds has authored.
Pemrydi RTU country-specific access guides
Reserve Meds has published 7 country-specific access guides for Pemrydi RTU. Each guide covers the regulatory pathway, the tertiary referral context, the documentation package, the indicative drug-only band, and the operational sequence Reserve Meds coordinates for that jurisdiction.
Bahrain
Read the Bahrain access guide for Pemrydi RTU.
Read the guideIndia
Read the India access guide for Pemrydi RTU.
Read the guideJordan
Read the Jordan access guide for Pemrydi RTU.
Read the guideKuwait
Read the Kuwait access guide for Pemrydi RTU.
Read the guidePakistan
Read the Pakistan access guide for Pemrydi RTU.
Read the guideQatar
Read the Qatar access guide for Pemrydi RTU.
Read the guideSri Lanka
Read the Sri Lanka access guide for Pemrydi RTU.
Read the guideOther countries not yet authored
Reserve Meds has authored country-specific access guides for Pemrydi RTU in the 7 jurisdictions listed above. If your case sits in a country that is not yet on this list, that does not mean a pathway is unavailable. It means we have not yet published the country-specific guide for Pemrydi RTU. The Reserve Meds case team will scope your case under the same named-patient or personal-import framework that governs the published guides.
Request a Pemrydi RTU access scope for your country
Related Reserve Meds resources
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating physician.
Editorial review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.